Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LillyDirect Foundayo vs LunaRx

LillyDirect Foundayo
Graded #165

Higher grade

vs+6
LunaRx
Graded #299

Lower grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 61.2/100.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +18
72
54
Dose & formulationLillyDirect Foundayo +7
59
52
Clinical oversightLunaRx +4
78
82
Labs & monitoringLunaRx +2
52
54
FulfillmentLillyDirect Foundayo +10
80
70
Contract termsEven
55
55
LillyDirect Foundayo · left barLunaRx · right bar

The numbers

MetricLillyDirect FoundayoLunaRx
WeighScore67.2/10061.2/100
GradeCC
Scorecard rank#165#299
SemaglutideNot disclosed$199/mo (starting dose, compounded)
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow
LunaRx

Graded #299 · C

Strengths

  • Pairs GLP-1 with muscle-protective peptides (e.g., CJC-1295/Ipamorelin, NAD+) to defend lean mass during fat loss
  • Structured, physician-directed off-ramp taper with GI-reset support instead of an indefinite prescription
  • Bilingual care in English and Spanish across intake, messaging, and consults
  • Care directed through a named independent medical group (CareNexus Clinic PC); $0 charged if you are not approved
  • Published clinical support hours (Mon–Fri, CT) with phone, email, and secure messaging; cancel anytime

Where it loses points

  • Only a "from $199/mo" starting price is published; tirzepatide and per-tier pricing are confirmed only after a provider review
  • Compounding pharmacy partners are not named on the site — a transparency gap
  • No LegitScript or PCAB verification is displayed
  • States served are not published; the site claims "telehealth nationwide" but the Terms limit service to states where LunaRx is licensed
  • Compounded medications are not FDA-approved (the site discloses this)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard